

**MIKE G. MARTIN, MD**  
**Medical Oncologist, The West Cancer Center**  
**Associate Professor of Medicine, The University of Tennessee**  
**Memphis, TN**

***Education:***

**University of Memphis**

Bachelor of Science, summa cum laude

Biology major, Chemistry minor

January 1996 - August 1999

- Studied Abroad in **Australia and New Zealand**, Summer of 1997
- Studied Abroad at the **University of Helsinki, Finland**, Fall of 1998

**University of Tennessee, College of Medicine**

Medical Doctorate with Highest Honors, August 1999 - May 2003

- Rotated in Recife, Brazil as a part of the **St. Jude Professional Oncology Experience** program, Summer 2000

**Duke University Medical Center**

Internship and Residency in Internal Medicine

June 2003 - June 2006

**Washington University in St. Louis School of Medicine**

Fellow in Medical Oncology

July 2006 - June 2009

- Post-doctoral fellow in lab of Matthew J Walter, MD, July 2007 - June 2009

***Honors and Awards:***

(1999) Summa cum laude, University of Memphis

(2003) Outstanding Medical Student Award - Neurology

(2003) Alpha Omega Alpha

(2003) Graduated University of Tennessee Medical School with Highest Honors

(2003) Faculty Medal - For Highest Academic Achievement (GPA 4.00) (University of Tennessee HSC)

(2008) Finalist for American Society of Hematology Fellow Research Training Award

(2012) Faculty of the Year - The West Clinic/University of Tennessee Division of Hematology/Oncology

(2014) Outstanding Attending Award - The University of Tennessee College of Medicine

(2014-15) Student Government Association Executive Council Excellence in Teaching Award for Outstanding Teaching and Genuine Concern for Students, The University of Tennessee HSC College of Medicine

(2015-16) The Marion Dugdale Outstanding Faculty Award - The West Cancer Center/ University of Tennessee Division of Hematology/Oncology

***Mentored awards:***

(2014) 15<sup>th</sup> Annual Fellows Travel Award to the 24<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Review (M Pandey)

(2015) Alpha Omega Alpha/University of Tennessee College of Medicine Resident Research Award (PE Prouet)

(2015) 16<sup>th</sup> Annual Fellows Travel Award to the 25<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Review (E Wiedower)

(2015) Medical Student Achievement in Research Award University of Tennessee College of Medicine (A Hahn)

(2015) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (O Jamy)

(2015) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (E Wiedower)  
(2015) American Society of Hematology Annual Meeting Abstract Achievement Award (E Wiedower)  
(2016) 17<sup>th</sup> Annual Fellows Travel Award to the 26<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Review (M Chi)  
(2016) 17<sup>th</sup> Annual Fellows Travel Award to the 26<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Review (G Yagmour)  
(2016) 17<sup>th</sup> Annual Fellows Travel Award to the 26<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Review (S Nasir)  
(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (M Crawley)  
(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (K Patel)  
(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (M Mirza)  
(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (N Vontela)  
(2016-17) American Society of Clinical Oncology Cancer Interest Group for Medical Students Award (E Vick)

***Board Certification:***

Internal Medicine (2006)  
Medical Oncology (2010)

***Medical licenses:***

Missouri (2008)  
Tennessee (2009 - active)  
Mississippi (2009 - active)

***Professional Societies and Organizations:***

Member of the American Society of Hematology (2006 to present)  
Member of the American Society of Clinical Oncology (2006 to present)

***Hospital and Clinical Appointments:***

Methodist Olive Branch (November 2013 - present)  
Health South Rehab of Memphis (December 2009 - present)  
Methodist Extended Care (October 2009 - present)  
Fayette County Hospital (August 2009 - present)  
St. Francis Bartlett (July 2009 - present)  
St. Francis Memphis (July 2009 - present)  
Baptist Metro (July 2009 - present)  
Methodist Healthcare Memphis Hospitals (August 2009 - present)

***Practice and Professional Experience:***

The West Clinic, Medical Oncologist, Memphis, TN (August 2009 - present)

***Teaching Experience:***

Assistant Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN (May 2012 - June 2015)  
Associate Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN (July 2015 - present)

***Invited lectures:***

1. "NSCLC " University of Tennessee Internal Medicine Morning Report (October 2012)

2. "Hodgkin's Disease" University of Tennessee Hematology and Oncology Fellowship lecture series (January 2013)
3. "Acute Myeloid Leukemia Diagnosis, Prognosis and Supportive Care" University of Tennessee Hematology and Oncology Fellowship lecture series (January 2013)
4. "GI Cancers" University of Tennessee Internal Medicine educational lecture series (January 2013)
5. "Lung Cancer" University of Tennessee Internal Medicine educational lecture series (January 2013)
6. "Medical Oncology for Surgeons" University of Tennessee Surgery monthly conference (January 2013)
7. "What's new in AML" West Clinic/University of Tennessee Medical Oncology meeting (March 2013)
8. "Avoiding Physician Burnout" Serving the Underserved curriculum, the Church Health Center (March 2013)
9. "Liquid Oncology Case presentations" University of Tennessee First Year Medical Student Pathophysiology Lecture (March 2013)
10. "Acute Myeloid Leukemia Treatment" University of Tennessee Hematology and Oncology Fellowship lecture series (April 2013)
11. "Exotic Liquid Oncology" University of Tennessee Hematology and Oncology Fellowship lecture series (May 2013)
12. "Primary CNS Tumors" University of Tennessee College of Pharmacy core lecture series (August 2013)
13. "Hodgkin's Disease Update" University of Tennessee Hematology and Oncology Fellowship lecture series (August 2013)
14. "Advances in Lung Cancer" University of Tennessee Internal Medicine educational lecture series (January 2014)
15. "Advances in GI Cancers" University of Tennessee Internal Medicine educational lecture series (January 2014)
16. "Leukemia" University of Tennessee Internal Medicine educational lecture series (January 2014)
17. "Acute Myeloid Leukemia 101" University of Tennessee Hematology and Oncology Fellowship lecture series (January 2014)
18. "How to become an oncologist" University of Tennessee Health Science Center lecture to M1 and M2's (February 2014)
19. "How to avoid physician burnout" Women in Medical Sciences (WIMS), of Tennessee Health Science Center (February 2014)
20. "Ma'am we have a problem, DLBCL" University of Tennessee Hematology and Oncology Fellowship lecture series (September 2014)
21. "I don't want any chemo! Hodgkin's disease" University of Tennessee Hematology and Oncology Fellowship lecture series (September 2014)
22. "Four cases of lung cancer and down the rabbit hole" University of Tennessee Internal Medicine educational lecture series (January 2015)
23. "Three GI cases and would you take adjuvant gemcitabine or FOLFIRINOX?" University of Tennessee Internal Medicine educational lecture series (January 2015)
24. "Leukemia and through the looking glass" University of Tennessee Internal Medicine educational lecture series (January 2015)
25. "Acute Myeloid Leukemia cases" University of Tennessee Hematology and Oncology Fellowship lecture series (February 2015)
26. "DLBCL" University of Tennessee Hematology and Oncology Fellowship lecture series (September 2015)
27. "Lung Cancer and Immunotherapy" University of Tennessee Internal Medicine educational lecture series (November 2015)
28. "Colorectal Cancer" University of Tennessee Internal Medicine educational lecture series (November 2015)
29. "The Acute Leukemias" University of Tennessee Internal Medicine educational lecture series (December 2015)
30. "Hodgkin Lymphoma" University of Tennessee Hematology and Oncology Fellowship lecture series (February 2016)
31. "Diagnosis and Prognosis of Acute Myeloid Leukemia" University of Tennessee Hematology and Oncology Fellowship lecture series (March 2016)
32. "Treatment of Acute Myeloid Leukemia" University of Tennessee Hematology and Oncology Fellowship lecture series (April 2016)

33. "Avoiding Physician Burnout" Serving the Underserved curriculum, the Church Health Center (April 2016)
34. "The Aggressive Lymphomas with a focus on ACLC and DLBCL" University of Tennessee Hematology and Oncology Fellowship lecture series (September 2016)
35. "Chronic Lymphocytic Leukemia Update" West Cancer Center Medical Oncology Meeting presentation (September 2016)

**Peer reviewed manuscripts:**

1. **Martin MG**, Arcasoy MO. Deferasirox versus deferoxamine. *Blood*. 2006; 108: 774 - 5.
2. **Martin MG**, Humphreys ME. Social consequence of disease in the American South, 1900 - World War Two. *South Med J*. 2006; 99: 862 - 4.
3. **Martin MG**, Ardatti A, Dunlay S, Abernethy AP, Blazing MB. Case report: Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia. *Chest*. 2007; 131: 290 -
4. **Martin MG**. Encephalopathy with myoclonic jerks resulting from ceftazidime therapy: an under-recognized potential side-effect when treating febrile neutropenia. *Leuk Lymphoma*. 2007; 48: 413-4.
5. **Martin MG**, Whitlatch NL, Shah B, Arepally GM. Case report: Successful treatment of thrombotic thrombocytopenic purpura in a Jehovah's witness without total plasma exchange. *Am J Hematology*. 2007; 82 (7): 679-81.
6. Morgensztern D, **Martin MG**, Lossos IS. Gene expression profiling in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2007; 48: 669 - 82.
7. **Martin MG**, Govindan R, Morgensztern D. Second-line therapy for esophageal cancer. *Expert Reviews Anticancer Therapy*. 2007; 7: 871-6.
8. Whitlatch NL, **Martin MG**, Shah BD, Arepally GM. Response to Boctor and Smith. *Am J Hematol*. 2008; 83(3): 256. [Epub ahead of print] 2007 Oct 4.
9. **Martin MG**, Abboud CN. Induction therapy for elderly patients with acute myeloid leukemia. *Blood Rev*. 2008; 22(6):311-20. [Epub ahead of print]. Jun 6 2008
10. **Martin MG**, DiPersio JD, Uy GL. Management of the advanced phases of Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. *Leuk Lymphoma*. 2009; 50(1)14-23.
11. **Martin MG**, Uy GL, Procknow E, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R. Allogeneic stem cell transplantation conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. *Bone Marrow Transplant*. 2009; 44(1)13-7.
12. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauer MA, **Martin MG**, Kasai Y, Walter MJ. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. *PLoS One*. 2009; 4(2)e4583. [Epub] 2009 Feb 25.
13. **Martin MG**, DiPersio JD, Uy G. Importance of durable response in CML. *Oncol Rev*. 2009; 3(1):59-70.
14. **Martin MG**, Vij R. Arterial thrombosis with thalidomide in the treatment of multiple myeloma, a single center case series and review of the literature. *Clin Lymphoma Myeloma*. 2009; 9(4):320-3.
15. **Martin MG**, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN. Cladribine in the treatment of Acute Myeloid Leukemia, a single institution experience. *Clin Lymphoma Myeloma*. 2009; 9(4):298-301. \*cited by the NCCN guidelines for the management of AML (2011-present).

16. **Martin MG**, Payton JE, Link DC. Dicer and outcomes in patients with Acute Myeloid Leukemia. *Leuk Research*. 2009; 33(8):e127.
17. **Martin MG**, Welch JS, Luo J, Ellis M, Graubert TA, Walter MJ. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. *Breast Cancer Res Treat*. 2009; 118(3): 593-8.
18. **Martin MG**, Walgren R, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, DiPersio JF, Vij R. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndrome. *Am J Hematol*. 2009; 84(9): 560-4.
19. **Martin MG**, Augustin KA, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, G-CSF, and idarubicin with or without gemtuzumab ozogamicin. *Am J Hematol*. 2009; 84 (11):733-7.
20. **Martin MG**, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ. Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. *Leukemia*. 2010 Sep; 24 (9): 1662-4 Epub 2010 Jul 29.
21. Cheuk DK, Billups CA, **Martin MG**, Roland CR, Ribeiro RC, Krasin MJ, Rodriguez-Galindo. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. *Cancer*. 2011; 117(1):197-206. [Epub ahead of print] 2010 Aug 24.
22. Benson AB 3<sup>rd</sup>, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakh MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, **Martin MG**, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal Cancer. *J Natl Compr Cancer Netw*, 2012 Dec 1:10(12): 1528-64.
23. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, **Martin MG**, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M. Acute myeloid leukemia, version 2.2013. *J Natl Compr Canc Netw*. 2013 Sep 1;11(9):1047-55.
24. Jacoby MA, **Martin MG**, Uy GL, Westervelt P, Dipersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN. Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia. *Am J Hematol*. 2014; 89(5):487-92. Jan 11. doi: 10.1002/ajh.23663.
25. Paulus EM, Fleming MD, Hendrix AA, Deneve JL, Dickson PV, Mathew A, **Martin MG**, Munene G. The evolving role of surgery for gastric lymphoma: From curative resection to surgical management of complications. *Am Surg*. 2014; 80(11):322-4.
26. Pandey M, **Martin MG**. Primary Angiosarcoma of the Breast: A case report and review of the literature. *World J Oncol*. 2014; 5(3):144-8.
27. Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, **Martin MG**. Seasonal variation in the presentation of thyroid cancer in the USA: An analysis of the Surveillance, Epidemiology and End Results Registry. *Cancer Causes Control*. 2014; 25(11):1583-5.
28. Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, **Martin MG**. Seasonal and Regional Variation of Thrombotic Thrombocytopenic Purpura in the United States: Insights from the Nationwide Inpatient Sample. *Am J Hematol*. 2014 Sept 17. doi: 10.1002/ajh.23853. [Epub ahead of print]
29. Giri S, Pathak R, Li B, Prouet P, **Martin MG**. Acute Megakaryocytic Leukemia is associated with inferior outcomes relative to other Acute Myeloid Leukemia morphologies. *Blood*; 2014 Dec 11; 124(25): 3833-4. doi: 10.1182/blood-2014-09-603415.

30. Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, **Martin MG**. Incidence trend of esophageal squamous cell carcinoma: An analysis of Surveillance Epidemiology and End Results (SEER) database. *Cancer Causes Control*. 2014 Nov 7. [Epub ahead of print].
31. Pathak R, Giri S, Aryal MR, Karmacharya P, **Martin MG**. Mortality, Length of Stay and Healthcare Costs of Febrile Neutropenia Related Hospitalizations among Patients with Breast Cancer in the United States. *Support Care Cancer*. 2015 Mar;23(3):615-7. doi: 10.1007/s00520-014-2553-0. Epub 2015 Jan 4. PMID: 25556610.
32. Pathak R, Giri S, Aryal MR, Karmacharya P, **Martin MG**. Lack of "Weekend Effect" on mortality for Pulmonary Embolism Admissions in 2011: Data from Nationwide Inpatient Sample. *Int J Cardiol*. 2015 Feb 1;180:151-3. doi: 10.1016/j.ijcard.2014.11.201. Epub 2014 Nov 26.
33. Fintel A, Jamy O, **Martin MG**. Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL): Does insurance and marital status influence outcome? *Clin Lymphoma Myeloma Leuk*. 2014 Dec 12. pii: S2152-2650(14)00541-2. doi: 10.1016/j.clml.2014.12.006. [Epub ahead of print]
34. Hahn A, Giri S, Yaghmour G, **Martin MG**. Ibrutinib has some activity in Richter's Syndrome. Accepted *Blood Cancer Journal* December 2014. *Blood Cancer J*. 2015 Jan 30;5:e277. doi: 10.1038/bcj.2014.98. No abstract available. PMID: 25635530
35. Pandey M, Giri S, Sutton G, **Martin MG**. Grade drives prognosis in localized primary angiosarcoma of the breast. Accepted *Clinical Breast Cancer* December 2014. *Clin Breast Cancer*. 2015 Aug;15(4):266-9. doi: 10.1016/j.clbc.2014.12.009. Epub 2015 Jan 3. PMID: 25659906
36. Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, **Martin MG**. Impact of hospital volume on outcomes of patients undergoing chemotherapy for Acute Myeloid Leukemia: a matched cohort study. Accepted *Blood* January 2015.
37. Hahn A, Giri S, Yaghmour G, **Martin MG**. Early Mortality in Acute Myeloid Leukemia. Accepted *Leukemia Research* February 2015.
38. Giri S, Pathak R, Yarlagadda V, Karmacharya P, Aryal MR, **Martin MG**. Meta-analysis of 21-Gauge versus 22-Gauge Aspiration Needle during Endobronchial Ultrasound Guided Transbronchial Needle Aspiration. Accepted *Journal of Bronchology and Interventional Pulmonology* February 2015. *J Bronchology Interv Pulmonol*. 2015 Apr;22(2):107-13. doi: 10.1097/LBR.000000000000159.
39. Jamy O, Yaghmour G, Hare F, **Martin MG**. SEER-analysis of outcomes for primary small cell carcinoma of the ovary. Accepted *Anticancer Research* February 2015. *Anticancer Res*. 2015 May;35(5):3091-5. PMID: 25964600
40. Giri S, Pathak R, Aryal MR, Karmacharya P, Raj Bhatt V, **Martin MG**. Second Primary Malignancies in Waldenstrom's Macroglobulinemia: A US population based study. Accepted *Cancer Causes and Control* February 2015.
41. Hare F, Giri S, Patel JK, Hahn A, **Martin MG**. A Population-Based Analysis of Outcomes for Small Cell Carcinoma of the Breast by Tumor Stage and the Use of Radiation Therapy. Accepted *Springer Plus* March 2015. *Springerplus*. 2015 Mar 21;4:138. doi: 10.1186/s40064-015-0913-y. eCollection 2015. PMID: 25853028
42. Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, **Martin MG**. Next Generation Sequencing and *in silico* analysis facilitate prolonged response to pazopanib in a patient with metastatic urothelial carcinoma of the renal pelvis. Accepted *JNCCN* May 2015.

43. Giri S, Pathak R, **Martin MG**, Bhatt VR. Survival of *de novo* and secondary acute promyelocytic leukemia: A propensity matched analysis of the SEER database. Accepted Leukemia and Lymphoma June 2015. Leuk Lymphoma. 2015 Jun 18:1-28. [Epub ahead of print]
44. Hahn AW, Jamy O, Nunnery S, Yagmour G, Giri S, Pathak R, **Martin MG**. How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia. Accepted Clinical Leukemia, Lymphoma and Myeloma June 2015.
45. Prouet PE, **Martin MG**. Rapid evolution of intracranial Myeloid Sarcoma in Four Weeks. Accepted Blood July 2015.
46. Hahn AW, Li B, Prouet P, Giri S, Pathak R, **Martin MG**. Acute megakaryocytic leukemia: What have we learned. Blood Rev. 2015 Jul 18. pii: S0268-960X(15)00060-0. doi: 10.1016/j.blre.2015.07.005. [Epub ahead of print] PMID: 26228843.
47. Ghimire S, Giri S, Pathak R, **Martin MG**. Sister Mary Joseph's nodule in a patient with metastatic small cell lung cancer. J Community Hosp Intern Med Perspect. 2015 Jun 15;5(3):27388. doi: 10.3402/jchimp.v5.27388. eCollection 2015.
48. Franklin RA, Giri S, Valasareddy P, Lands LT, **Martin MG**. Comparative survival of patients with anal adenocarcinoma (AA), squamous cell carcinoma of the anus (SCCA), and rectal adenocarcinoma (RA). Accepted July 2015 to Clinical Colorectal Cancer.
49. [Incidence of breast cancer among female survivors of Hodgkin lymphoma: a US-population-based trend analysis from 1973 to 2011.](#)  
Giri S, Pathak R, **Martin MG**, Bhatt VR.  
Blood. 2015 Oct 8;126(15):1861-3. doi: 10.1182/blood-2015-05-647412. Epub 2015 Aug 17. No abstract available.  
PMID: 26282539
50. [Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.](#)  
Wiedower E, Jamy O, **Martin MG**.  
Anticancer Res. 2015 Nov;35(11):6287-90.  
PMID: 26504064
51. [Seasonal variation of immune thrombocytopenic purpura related hospitalizations among adults in the USA: analysis of the nationwide inpatient sample database.](#)  
Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, **Martin MG**.  
Ther Adv Hematol. 2015 Aug;6(4):217-8. doi: 10.1177/2040620715582146. No abstract available.  
PMID: 26288716 **Free PMC Article**
52. [Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis.](#)  
Giri S, Chi M, Johnson B, McCormick D, Jamy O, Bhatt VR, **Martin MG**.  
Leuk Res. 2015 Dec;39(12):1342-6. doi: 10.1016/j.leukres.2015.09.011. Epub 2015 Sep 12.  
PMID: 26427729
53. [Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.](#)  
Giri S, Pathak R, **Martin MG**, Bhatt VR.  
Ther Adv Hematol. 2015 Dec;6(6):308-12. doi: 10.1177/2040620715607416. No abstract available.  
PMID: 26622999 **Free PMC Article**
54. [Precision medicine: lessons learned from the SHIVA trial.](#)  
Hahn AW, **Martin MG**.  
Lancet Oncol. 2015 Dec;16(16):e580-1. doi: 10.1016/S1470-2045(15)00458-1. No abstract available.  
PMID: 26678198

55. [Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic Syndrome.](#)  
Johnson B, Giri S, Nunnery SE, Wiedower E, Jamy O, Yaghmour G, Chandler JC, **Martin MG.**  
Clin Lymphoma Myeloma Leuk. 2016 Jan 12. pii: S2152-2650(16)00021-5. doi: 10.1016/j.clml.2016.01.002. [Epub ahead of print]  
PMID: 26837475
56. [Treatment Disparities Faced by Undocumented Workers From Low- and Middle-Income Countries in the United States With Hematologic Malignancies.](#)  
Nunnery SE, Fintel AE, Jackson WC, Chandler JC, Ugwueke MO, **Martin MG.**  
J Natl Compr Canc Netw. 2016 Apr;14(4):483-6. No abstract available.  
PMID: 27059195
57. [Under-recognition of hemophagocytic syndrome in United States' rural, non-teaching hospitals.](#)  
Jamy O, Nunnery S, Giri S, Wiedower E, Johnson B, Yaghmour G, **Martin MG.**  
Leuk Lymphoma. 2016 Apr 18:1-3. [Epub ahead of print] No abstract available.  
PMID: 27087428
58. Hahn A, **Martin MG.** RE: Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. <http://www.bloodjournal.org/content/127/14/1752.e-letters#>
59. [Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.](#)  
McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein M, Feldman R, Chandler JC, **Martin MG.**  
Breast Cancer Res Treat. 2016 Jun 21. [Epub ahead of print]  
PMID: 27329168
60. [Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.](#)  
Hahn AW, Giri S, Pathak R, Bhatt VR, **Martin MG.**  
Anticancer Res. 2016 Aug;36(8):4051-5.  
PMID: 27466512
61. [Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 and older.](#)  
Thompson MP, Waters TM, Kaplan EK, McKillop CN, **Martin MG.**  
Blood. 2016 Jun 29. pii: blood-2016-05-716662. [Epub ahead of print] No abstract available.  
PMID: 27357700
62. [Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors.](#)  
Yaghmour G, Pandey M, Ireland C, Patel K, Nunnery S, Powell D, Baum S, Wiedower E, Schwartzberg LS, **Martin MG.**  
Anticancer Res. 2016 Aug;36(8):4033-8.  
PMID: 27466509
63. [Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia.](#)  
Wiedower E, Hare F, Arthur A, Chandler J, **Martin MG.**  
Ther Adv Hematol. 2016 Aug;7(4):231-2. doi: 10.1177/2040620716648563. Epub 2016 May 17. No abstract available.  
PMID: 27493713
64. [Genomic alterations in neuroendocrine cancers of the ovary.](#)  
Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC, Pandey M, **Martin MG.**  
J Ovarian Res. 2016 Aug 26;9(1):52. doi: 10.1186/s13048-016-0259-2.  
PMID: 27566252



***Current Committee, teaching positions and offices held:***

1. National Comprehensive Cancer Network (NCCN) guidelines committee on Acute Myeloid Leukemia (2012 - present).
2. Site Director University of Tennessee Hematology and Oncology Fellowship, Methodist University Hospital (October 2012 - present)
3. Faculty Advisor University of Tennessee Medical Student Hematology and Oncology Interest Group (March 2013 - present).
4. National Comprehensive Cancer Network (NCCN) guidelines committee on Non-Hodgkin Lymphoma (2016 - present).
5. National Comprehensive Cancer Network (NCCN) guidelines committee on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2016 - present).

***Past Committees, teaching positions and offices held:***

1. Chair of Hematology Research Committee at the Accelerated Community Oncology Research Network (ACORN) (January 2010 - March 2012).
2. Elected Division representative for Hematology and Oncology Baptist Hospital Memphis (January 2011-December 2012) .
3. National Comprehensive Cancer Network (NCCN) guidelines committee on Colon, Rectal and Anal cancers (2012)
4. Co-Chair Methodist University Hospital/University of Tennessee Joint Medical Oncology and Surgical Oncology conference (2013).
5. Co-preceptor Methodist Oncology Pharmacy residency (September 2011 - June 2014).
6. Lincoln Memorial University - DeBusk College of Osteopathic Medicine preceptor for Hematology and Oncology rotation (July 2012).
7. Site principal investigator (West Clinic) and Executive Committee member of the Blood Cancer Research Program in conjunction with Dana Farber Cancer Institute (June 2013 - January 2016).
8. Chair Methodist University Hospital Hematology and Oncology Morbidity and Mortality Conference (April 2013 - December 2015).
9. Preceptor Christian Brothers University Physician Assistant program (July 2013 - June 2015).
10. Preceptor University of Tennessee Physician Assistant program (April 2015 - December 2016)

***Consulting:***

- (2007) Genzyme Oncology Leukemia Advisory Board
- (2008) Bayer Oncology Advisory Board
- (2009) GSK Oncology Advisory Board
- (2009) Lilly Oncology Advisory Board
- (2009) Coronado Biosciences

***Research and Other External Support:***

***Investigator Sponsored Trials:***

1. Vij R, **Martin MG**, et al. Non-myeloablative conditioning regimen for allogeneic transplantation with thymoglobulin, cytarabine, and clofarabine for myelodysplastic syndrome and acute myeloid leukemia. 11/07-6/08. Budget: \$113,023; Funded by Genzyme. Results published in Bone Marrow Transplant. 2009; 44(1)13-7.
2. Abboud CN, **Martin MG**, et al. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. Funded 3/08; Open 1/09. Budget: \$236,270; Funded by Genzyme. Results published in Am J Hematol. 2014; 89(5):487-92. Jan 11. doi: 10.1002/ajh.23663.

***Research Grant:***

1. Stein M, Wiedower E, Chandler JC, **Martin MG**. *In Silico* Analysis of Variants of Unknown Significance Identified by Next-Generation Sequencing to Predict Response to Platinum-Based Therapy in Patients

with Metastatic Non-Small Cell Lung Cancer. West Cancer Center Research Award July 2016-June 2017: \$10,000.

**Site Principle Investigator:**

1. A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. SPONSOR: Allos Therapeutics, Inc. PROTOCOL NO: PDX-015 (Feb 2011 - April 2012).
2. Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. SPONSOR: Lilly PROTOCOL NO: H3E-MC-S132 (a) (September 2010 - Present).
3. A phase II, multi-center, single arm, open label study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: CLBH589DUS71. (October 2010 - June 2011).
4. A randomized, double-blind, placebo-controlled, multi-center phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: CRAD001N2301 (October 2010 - present).
5. A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation. SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: CTKI258A2204 (October 2010 - present).
6. A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO). SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: ICL670A2302 (October 2010 - present).
7. Safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (December 2013 - present).

**Invited Publications/Book Chapters:**

1. Picus J, **Martin MG**. *Gastrointestinal Complications of Chemotherapy*. The Chemotherapy Source Book, Michael C. Perry Ed. 4th edition. 2007:197-208.
2. **Martin MG**, Welch J. *The Leukemias*. Washington Manual Hematology and Oncology Subspecialty Consult, 2nd edition, 2008.
3. Welch J, **Martin MG**. *The Myeloproliferative disorders*. Washington Manual Hematology and Oncology Subspecialty Consult, 2nd edition, 2008.
4. **Martin MG**. *Melanoma*. Washington Manual Hematology and Oncology Subspecialty Consult, 2nd edition, 2008.
5. **Martin MG**, Vij R. Monographs on *decitabine, thiotepa, thalidomide, lenalidomide* and *bortezomib*. Essential Cancer Pharmacology: The Prescriber's Guide. Cambridge University Press. Govindan R and S Maier, eds. 2009.
6. **Martin MG**, Welch JS, Abboud CN. *Novel therapies and molecular targets in acute lymphoblastic leukemia*. Adult Acute Lymphocytic Leukemia. Humana, Advani A and HM Lazarus eds. 2009.
7. **Martin MG**, Walter MJ, Graubert TA. Animal models of Myelodysplastic syndromes. In press.

**Peer Reviewer:**

Palliative Care: Research and Treatment (2008)  
Clinical Lymphoma and Myeloma (2008)  
Expert Opinion on Pharmacotherapy (2009)  
Journal of the National Comprehensive Cancer Network (2012, 2016)

**Published Abstracts:**

1. **Martin MG**, Grubaugh J. Examination of the possible leaking of leachate from the Shelby County Penal landfill into the Wolf River, Memphis, TN. Poster presentation at the 1998 National Conference on Undergraduate Research, Volume IV, p1240-4.
2. **Martin MG**, Ardati A, Dunlay S. Case report: Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia. Poster presentation at the 2006 North Carolina chapter of the American College of Physicians annual meeting.
3. **Martin MG**, Currow DC, Abernethy AP. Predictors of fatigue and quality of life in a prospective palliative care cohort. Poster presentation at the 2006 ASCO Annual Conference. Abstract # 8571, p485s.
4. **Martin MG**, Currow DC, Abernethy AP. Breadth of prescribing in palliative care, a prospective cohort study. Poster presentation at the 2006 annual Society of General Internal Medicine Conference. April 2006, Abstract # 156394, p69.
5. Abernethy AP, Patwardhan MB, Herndon JE, Dowell J, Rowe KL, **Martin MG**, Zafar Y, and Morse M. Tracking performance: Can oncology practices respond to the new quality measures? Poster presentation at the ASCO GI Conference 2007, Abstr # 264.
6. Zafar Y, Provenzale DT, Herndon JE, Dowell J, Patwardhan MB, Rowe KL, **Martin MG**, Morse M, and Abernethy AP. The impact of comorbidity on diagnosis and treatment of colorectal cancer (CRC). Poster presentation at the ASCO GI Conference 2007, Abstr # 261.
7. Patwardhan M, Herndon JE, Rowe K, **Martin MG**, Zafar Y, Morse M, Abernethy AP. Can we accurately track colorectal cancer management using ASCO/NCCN quality measures? Poster Presentation at the Annual Meeting of the Duke Comprehensive Cancer Center. Durham, North Carolina. March 12, 2007. Abstract book page 174.
8. Zafar Y, Provenzale D, Herndon JE, Dowell J, Patwardhan M, Rowe K, **Martin MG**, Morse M, Abernethy AP. The impact of comorbidity on diagnosis and treatment of colorectal cancer (CRC). Poster Presentation at the Annual Meeting of the Duke Comprehensive Cancer Center. Durham, North Carolina. March 12, 2007. Abstract book page 199.
9. Rowe K, Patwardhan M, Herndon JE, **Martin MG**, Zafar Y, Morse M, Abernethy AP. Choice of adjuvant and first-line metastatic chemotherapy (CT) for colorectal cancer (CRC) treated in the Carolinas. Poster presentation at the 2007 ASCO Annual Conference. Abstract number 36147.
10. Abernethy AP, **Martin MG**, Currow DC. Predictors of fatigue and quality of life in a prospective palliative care cohort. Poster presentation at the Multinational Association for Supportive Care in Cancer 2007 Symposium. St. Gallen, Switzerland. June 27-30, 2007. *Supportive Care in Cancer* 2007; In press. Abstract number pending.
11. **Martin MG**, Wang-Gillam A, Atif A, Fong T, Gao F, Govindan R, Morgensztern D. Second-line systemic therapy for esophageal cancer. ASCO 2008; Abstract 15623.
12. **Martin MG**, Uy G, Procknow E, Walter MJ, Graubert TA, Tomasson M, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R. Allogeneic stem cell transplantation conditioning for MDS and AML with clofarabine, cytarabine and ATG. ASH 2008; Abstract 4427.

13. **Martin MG**, Welch JS, Augustin K, Hladnick L, Abboud CN. Cladribine in the treatment of acute myeloid leukemia. ASH 2008; Abstract 4032.
14. **Martin MG**, Walgren R, Procknow E, Westervelt P, Abboud CN, Cashen AF, Uy G, Stockerl-Goldstein K, Gao F, DiPersio JF, R Vij. Azacitidine-induced changes in the MDS methylome are associated with clinical responses. ASH 2008; Poster presentation, Abstract 2691.
15. **Martin MG**, Cashen AF. SEER analysis of Subcutaneous Panniculitis-like T-cell lymphoma (SPTL). ASCO 2009; abstract e19527.
16. **Martin MG**, Jacoby M, Deych E, Graubert TA, Walter MJ. BRCA1 and BRCA2 nucleotide variants in young women with therapy related acute myeloid leukemia. Washington University Hematopoiesis Development and Malignancy Program Retreat, Oral presentation, abstract 1.
17. Kilannin K, Chen TH, Tibbitts J, **Martin MG**, Walter MJ. B-Cell Progenitors Are Reduced in *Hspa9* haploinsufficient Mice. ASH 2011; Abstract 3829.
18. Jacoby M, **Martin MG**, Reineck T, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Uy GL, Vij R, Abboud CN. Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia. ASH 2011; Abstract 3633.
19. **Martin MG**, Fryar B, Danesi H, Schwartzberg LS. Phase IB study of an all-oral chemotherapy regimen, tesetaxel plus capecitabine, in patients with advanced solid tumors. ASCO 2012; Abstract 3085.
20. Vontela NR, Naini P, Shuman M, **Martin MG**. CLAG - A novel therapeutic option for secondary myelofibrosis, TN ACP; Nov 2012.
21. Martin TG, Panjabi S, Kerr J, **Martin MG**, Walker MS. Association Of Treatment Induced Peripheral Neuropathy (TIPN) With Treatment Patterns and Outcomes In Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM)  
ASH 2013; Abstract 1750.
22. Martin TG, Panjabi S, Kerr J, **Martin MG**, Walker MS. Association of Treatment Induced Peripheral Neuropathy with Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma. Poster presentation. Academy of Managed Care Pharmacy (AMCP) and The Journal of Managed Care Pharmacy (JMCP) 26th Annual Meeting & Expo in Tampa, Florida April 1-4, 2014.
23. Jamy O, Yagmour G, Hare F, Chandler JC, Stelts S, Azari L, **Martin MG**. SEER analysis of outcomes for primary small cell carcinoma of the ovary. ASCO 2014; Abstract e16512.
24. Hare F, Patel JK, Fenton MJ, **Martin MG**. SEER analysis of outcomes for primary small cell carcinoma of the breast. ASCO 2014; Abstract e12040.
25. Wiedower E, Chandler JC, Pallera AM, Johnson RA, Munene G, Dickson P, Deneve JL, Fleming MD, Tauer KW, Schwartzberg LS, **Martin MG**. Effect of rituximab on outcomes in gastric B-cell lymphomas and on early mortality in gastric DLBCL. ASCO 2014; Abstract e19501.
26. Yagmour G, Johnson BC, Lawson RD, **Martin MG**. Insurance and outcomes for classical Hodgkin lymphoma. ASCO 2014; Abstract e19505.
27. Laubach JP, Raje N, Armand P, Schlossman RL, Rosenblatt J, Matous JV, Hedlund J, **Martin MG**, Reynolds C, Shain K, Zackon I, Stampleman L, Boswell EN, Chuma S, Handisides DR, Kroll S, Ghobrial IM, Anderson KC, Richardson PG. Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). ASCO 2014; Abstract 8534.

28. Pandey M, Sutton GR, Portnoy DC, Tauer KW, Schwartzberg LS, Dickson P, **Martin MG**. Relationship of grade to prognosis in localized primary angiosarcoma of the breast (PAOB). ASCO 2014; Abstract 10559.
29. Fintel A, Jamy O, Chandler JC, **Martin MG**. Social connectivity and outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). ASCO 2014; Abstract 7049.
30. Laubach JP, Raje N, Armand P, Schlossman RL, Rosenblatt J, Matous JV, Hedlund J, **Martin MG**, Reynolds C, Shain K, Zackon I, Stampleman L, Boswell EN, Chuma S, Handisides DR, Kroll S, Ghobrial IM, Anderson KC, Richardson PG. Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). EHA 2014; Abstract P360.
31. Wiedower E, Chandler JC, **Martin MG**. The addition of rituximab to chemotherapy increases early mortality in gastric DLBCL but not gastric MALTomas. ASH Lymphoma Biology Meeting 2014; poster number 103.
32. Pandey M, Sutton GR, Portnoy DC, Tauer KW, Schwartzberg LS, Dickson P, **Martin MG**. Relationship of grade to prognosis in localized primary angiosarcoma of the breast (PAOB). Poster presentation 24<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Reviews 2014.
32. Hare F, Patel J, Fenton M, **Martin MG**. The effect of adjuvant radiation on survival for patients with resected localized or regional primary small cell carcinoma of the breast. ASCO 2014 Breast Cancer Symposium; Abstract 87.
33. Yaghmour G, Hahn A, **Martin MG**. Age and Population-Based Early Mortality Rate (EMR) in Acute Myeloid Leukemia (AML) Versus the EMR Reported By SWOG. ASH Annual Meeting 2014; Abstract 3665.
34. Giri S, Pathak R, Li B, Prouet P, **Martin MG**. Acute Megakaryocytic Leukemia (AMeGL) is associated with inferior outcomes relative to other Acute Myeloid Leukemia (AML) morphologies. ASH Annual meeting 2014; Abstract 2285.
35. Giri S, Pathak R, Aryal MR, Karmacharya P, **Martin MG**. Weekend versus weekday mortality for Thrombotic Thrombocytopenic Purpura (TTP) related hospitalizations in the United States: Data from the National Inpatient Sample. ASH Annual meeting 2014; Abstract 4863.
36. Laubach JP, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Matous JV, Hedlund J, **Martin MG**, Reynolds C, Shain K, Zackon I, Stampleman L, Boswell EN, Chuma S, Liguori R, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM. A Phase 1/2 Trial of TH-302 and Dexamethasone Without or With Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma. ASH Annual meeting 2014; Abstract 2142.
37. Prouet P, Giri S, Pathak R, Li B, **Martin MG**. Acute megakaryocytic leukemia is associated with inferior outcomes relative to other acute myeloid leukemia (AML) morphologies. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Oral presentation, abstract 2.
38. Giri S, Pathak R, Aryal MR, Karmacharya P, **Martin MG**. Weekend versus weekday mortality for Thrombotic Thrombocytopenic Purpura (TTP) related hospitalizations in the United States: Data from the National Inpatient Sample. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 34.
39. Hahn A, Giri S, Yaghmour G, **Martin MG**. Early Mortality in Acute Myeloid Leukemia. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 38.
40. Jamy O, Yaghmour G, Hare F, **Martin MG**. SEER analysis of outcomes for primary small cell carcinoma of the ovary. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 42.

41. Pandey M, Portnoy DC, Tauer K, Schwartzberg L, Dickson P, **Martin MG**. Grade drives prognosis in localized primary angiosarcoma of the breast (PAOB). Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 57.
42. Patel JK, Hare F, Fenton M, **Martin MG**. Adjuvant Radiation Does Not Improve Survival for Patients with Resected Localized or Regional Primary Small Cell Carcinoma of the Breast (SCCB). Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 59.
43. Wiedower E, Chandler J, **Martin MG**. The addition of rituximab to chemotherapy increases early mortality in gastric DLBCL but not gastric MALTomas. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 80.
44. Hahn A, Giri S, Pathak R, Bhatt VR, **Martin MG**. The effect of adjuvant radiotherapy on survival in locoregional urothelial malignancies of the upper urinary tract. ASCO 2015 annual meeting abstract e15636.
45. Pathak R, Giri S, **Martin MG**, Bhatt VR. Survival of BCR-ABL positive and negative chronic myeloid leukemia: A propensity matched analysis of the Surveillance, Epidemiology and End Results database. ASCO 2015 annual meeting abstract e18053.
46. Giri S, Pathak R, Bhatt VR, **Martin MG**. Impact of hospital volume on outcomes of patients undergoing chemotherapy for Acute Myeloid Leukemia (AML): a matched cohort study. ASCO 2015 annual meeting abstract e18067.
47. Franklin R, Giri S, Valasareddy P, Pathak R, **Martin MG**. A population based comparison of survival among patients with anal adenocarcinoma (AA), anal squamous cell carcinoma (ASCC), and rectal adenocarcinoma (RA). ASCO 2015 annual meeting abstract e14500.
48. Porter J, Chi MT, Giri S, McCormick D, **Martin MG**. Prognosis and outcomes of adult secondary acute lymphoblastic leukemia (sALL). ASCO 2015 annual meeting abstract e18061.
49. Wiedower E, Jamy OH, **Martin MG**. Induction of acute myeloid leukemia (AML) with Idarubicin, Cytarabine and Cladribine (ICC). ASCO 2015 annual meeting abstract e18048.
50. Pathak R, Giri S, **Martin MG**, Bhatt VR. Survival of de novo and secondary acute promyelocytic leukemia: A propensity matched analysis of the Surveillance, Epidemiology and End Results database. ASCO 2015 annual meeting abstract xx, poster presentation.
51. Laubach JP, Raje SR, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, **Martin MG**, Reynolds C, Shain, KH, Zackon I, Stampleman L, Boswell EN, Chuma S, Liguori R, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM. Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia activated prodrug combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). ASCO 2015 Annual meeting poster presentation.
52. Wiedower E, Giri S, Fintel A, Prouet P, Paulus E, Chandler JC, **Martin MG**. The addition of rituximab to chemotherapy decreased rates of primary surgery for gastric DLBCL without increasing early mortality. Poster Presentation ASH Hematologic Malignancy meeting abstract no 45. Poster presentation ASH Annual meeting abstract no 4475.
53. Jamy O, Giri S, Wiedower E, Johnson B, Nunnery S, Chandler JC, **Martin MG**. Under-Recognition of Hemophagocytic Lymphohistiocytosis in United States Rural, Non-Teaching Hospitals. Poster presentation ASH Hematologic Malignancy meeting abstract no 44. Poster presentation ASH Annual meeting abstract no 2079.
54. Giri S, Nunnery S, Naseer S, **Martin MG**. Outcome of adolescents and young adults with acute myeloid leukemia (AML) as compared to pediatric AML patients: Real world data from SEER registry. Poster presentation ASH Hematologic Malignancy meeting abstract no 18. Poster presentation ASH Annual meeting abstract no 4484.

55. Johnson B, Giri S, Nunnery S, Wiedower E, Chander JC, **Martin MG**. Comorbidities Drive Outcomes for Both Malignancy and Non-Malignancy Associated Hemophagocytic syndrome. Poster presentation ASH Hematologic Malignancy meeting abstract no 71. . Poster presentation ASH Annual meeting abstract no 3261.
56. Weatherall TJ, Denbo JW, Sharpe JP, **Martin MG**, Ismail M, O'Brien T, Groshart K, Gupta R, Behrman SW, Deneve JL, Munene G, Dickson PV. Treatment of Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors. Oral presentation 11th Annual Academic Surgical Congress, February 2-4, 2016 in Jacksonville, FL.
57. Michael P Thompson, Teresa M Waters, Erin Kaplan, Caitlin N McKillop, **Martin MG**. Hospital volume and post-discharge mortality in Medicare beneficiaries aged 65 and older with acute leukemia. Poster presentation at the ASCO 2016 Annual Meeting abstract no. 6560.
58. Michael P Thompson, Teresa M Waters, Erin Kaplan, Caitlin N McKillop, **Martin MG**. The volume-outcome relationship in emergent vs. non-emergent admissions for acute leukemia in Medicare beneficiaries aged 65 and older, ASCO 2016 Annual Meeting abstract no. e18109.
59. Teresa M Waters, Michael P Thompson, Erin Kaplan, Caitlin N McKillop, **Martin MG**. The volume-outcome relationship in Medicare beneficiaries aged 65 and older with acute myeloid leukemia and acute lymphocytic leukemia, ASCO 2016 Annual Meeting abstract no. e18110.
60. Catherine Gorman Ireland, Muhammad Mudassir Mirza, Alexandria Tran, Jason Claud Chandler, Monika Metzger, **Martin MG**. Impact of provider volume on outcomes of patients with Hodgkin lymphoma, ASCO Annual Meeting abstract no. e18203.
61. George Yaghmour, Omer HASSAN Jamy, Philippe Prouet, Manjari Pandey, **Martin MG**. Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO), ASCO 2016 Annual Meeting abstract no. e17053.
62. Brennan McCullar, Manjari Pandey, Felicia Hare, Kruti Patel, Matthew Stein, Melissa Crawley, George Yaghmour, Rebecca Feldman, **Martin MG**. Genomic landscape of small cell carcinoma of the breast (SCCB) contrasted to small cell carcinoma of the lung (SCLC), ASCO 2016 Annual Meeting abstract no. e23281.
63. George Yaghmour, Manjari Pandey, Catherine Gorman Ireland, Kruti Patel, Sarah Elizabeth Nunnery, Daniel Powell, Scott Baum, Eric Wiedower, Lee Steven Schwartzberg, **Martin MG**. Role of genomic instability in immunotherapy with checkpoint inhibitors. Poster presentation at the ASCO Annual Meeting abstract no. 3052.
64. Syed Sameer Nasir, Smith Giri, Sarah Elizabeth Nunnery, Eric Wiedower, **Martin MG**. Outcomes of adolescents and young adults (AYAs) compared to pediatric patients with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL): Real world data from the SEER registry, ASCO 2016 Annual Meeting abstract no. e18506.
65. Mirza M, McCullar B, **Martin MG**. Therapy related Myeloid and Lymphoid Neoplasms in BRCA mutated Breast and Ovarian Cancer patients. ASH Hematologic Malignancies 2016 Poster Abstract 10; ASH Annual Meeting 2016 abstract 5115.
66. Vonela NR, Byrd K, McCullar B, **Martin MG**. Multi-Database Description of Primary Splenic Diffuse Large B-cell Lymphoma. ASH Hematologic Malignancies 2016 Poster abstract 39; ASH Annual Meeting 2016 abstract 5399.
67. Patel D, Riney J, Hahn A, Stein M, **Martin MG**. Distribution of 9p24 Abnormalities in Hematologic Malignancies with an Emphasis on Diffuse Large B-cell lymphoma. ASH Hematologic Malignancies 2016 Poster abstract 40; ASH Annual Meeting 2016 Poster abstract 1866.
68. Patel K, Lee SS, Valasareddy P, Vontela N, **Martin MG**. Genetic Analysis of B-cell Lymphomas

Associated with Hemaphagocytic Lymphohistiocytosis. ASH Hematologic Malignancies 2016 Poster abstract 42; ASH Annual Meeting 2016 abstract 5315.

69. Crawley MA, Stein M, Patel K, **Martin MG**. Clinical Trial Availability in Adolescent and Young Adult Patients with Non-Hodgkin Lymphoma. ASH Hematologic Malignancies 2016 Poster abstract 44; ASH Annual Meeting 2016 abstract 5937.

70. Stein M, Riney J, Patel D, Hahn A, **Martin MG**. Increased Prevalence of t(8;9)(p21-23;p23-24) Translocations within 9p24 Abnormalities in Patients with Myeloid Malignancies Identified from the Mitelman database. ASH Hematologic Malignancies 2016 Poster abstract 67; ASH Annual Meeting 2016 Poster abstract 1935.

71. Giri U, **Martin MG**. Survival Outcomes in Grade 3 Follicular Lymphoma Prior to and after the Introduction of Rituximab - an Analysis Based on the Surveillance, Epidemiology, and End Result Registry Database. ASH Annual Meeting 2016 Poster abstract 2967.

***Other publications:***

1. Writer for Smartest Oncologist in America ([www.thesmartestoncologist.com](http://www.thesmartestoncologist.com)), August 2007 - August 2012.

2. **Martin MG**. Monographs on *Sources of stem cells, Target CD34 dose, Engraftment, Prognostic scoring and staging*, and *SOS/VOD* in the Washington University Guide to Bone Marrow Transplantation (2008).